Ultime notizie per US Physical Therapy (NYSE:USPH) Azioni

US Physical Therapy

US Physical Therapy Inc through its subsidiaries operates outpatient physical therapy clinics that provide pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers, and neurological-related injuries. The principal sources of payment for the clinics' services are managed care programs, commercial health insurance, Medicare/Medicaid, workers' compensation insurance, and proceeds from personal injury cases. Its operating segment includes Physical therapy operations and Industrial injury prevention services. The company generates maximum revenue from the Physical therapy operations segment.

Long Ideas

News

Insider Trades

Pre-Market Outlook

Markets

Trading Ideas

CECO

ESTC

USPH

Gli insider acquistano azioni chiave: scopri i dettagli degli investimenti milionari su Elastic, US Physical Therapy e altre società.

Questi insider puntano su 4 azioni chiave: ecco su cosa investono

US Physical Therapy Inc

Barrington Research analyst Michael Petusky maintains US Physical Therapy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USPH#NYSE">USPH</a>) with a Outperform and maintains $108 price target.

Price Target

Analyst Ratings

Barrington Research Maintains Outperform on US Physical Therapy, Maintains $108 Price Target

Revealing a significant insider sell on November 12, Graham Reeve, COO at US Physical Therapy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USPH#NYSE">USPH</a>), as per the latest SEC filing.
What Happened: According to a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000885978/000095017024125739//Archives/edgar/data/885978/000095017024125739/0000950170-24-125739-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday, Reeve sold 1,724 shares of US Physical Therapy. The total transaction value is $166,003.
Monitoring the market, US Physical Therapy's shares down by 0.0% at $92.1 during Wednesday's morning.
<h3>Get to Know US Physical Therapy Better</h3>
US Physical Therapy Inc through its subsidiaries operates outpatient physical therapy clinics that provide pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers, and neurological-related injuries. The principal sources of payment for the clinics' services are managed care programs, commercial health insurance, Medicare/Medicaid, workers' compensation insurance, and proceeds from personal injury cases. Its operating segment includes Physical therapy operations and Industrial injury prevention services. The company generates maximum revenue from the Physical therapy operations segment.
<h3>Understanding the Numbers: US Physical Therapy's Finances</h3>
Positive Revenue Trend: Examining US Physical Therapy's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 0.5% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Key Insights into Profitability Metrics:
<ul>
<li>
Gross Margin: The company shows a low gross margin of 17.34%, suggesting potential challenges in cost control and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): US Physical Therapy's EPS lags behind the industry average, indicating concerns and potential challenges with a current EPS of 0.39.
</li>
</ul>
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.53.
Financial Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: US Physical Therapy's stock is currently priced at a premium level, as reflected in the higher-than-average P/E ratio of 104.66.
</li>
<li>
Price to Sales (P/S) Ratio: A higher-than-average P/S ratio of 2.15 suggests overvaluation in the eyes of investors, considering sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): A high EV/EBITDA ratio of 22.77 positions the company as being more valued compared to industry benchmarks.
</li>
</ul>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Navigating the Impact of Insider Transactions on Investments</h3>
Insider transactions should be considered alongside other factors when making investment decisions, as they can offer important insights.
Considering the legal perspective, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, according to Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Nevertheless, insider sells may not necessarily indicate a bearish view and can be influenced by various factors.
<h3>Essential Transaction Codes Unveiled</h3>
When analyzing transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> tend to focus on those in the open market, detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase,while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000885978">Check Out The Full List Of US Physical Therapy's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

COO Of US Physical Therapy Makes $166K Sale

During the last three months, 5 analysts shared their evaluations of US Physical Therapy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USPH#NYSE">USPH</a>), revealing diverse outlooks from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $104.4, along with a high estimate of $108.00 and a low estimate of $90.00. This current average represents a 6.79% decrease from the previous average price target of $112.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1731006043_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The analysis of recent analyst actions sheds light on the perception of US Physical Therapy by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Petusky</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$108.00</td>
<td>$108.00</td>
</tr>
<tr>
<td>Michael Petusky</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$108.00</td>
<td>$108.00</td>
</tr>
<tr>
<td>Joanna Gajuk</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$90.00</td>
<td>$114.00</td>
</tr>
<tr>
<td>Michael Petusky</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$108.00</td>
<td>$108.00</td>
</tr>
<tr>
<td>Michael Petusky</td>
<td>Barrington Research</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$108.00</td>
<td>$122.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to US Physical Therapy. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of US Physical Therapy compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of US Physical Therapy's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of US Physical Therapy's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/USPH/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on US Physical Therapy analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>About US Physical Therapy</h2>
US Physical Therapy Inc through its subsidiaries operates outpatient physical therapy clinics that provide pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers, and neurological-related injuries. The principal sources of payment for the clinics' services are managed care programs, commercial health insurance, Medicare/Medicaid, workers' compensation insurance, and proceeds from personal injury cases. Its operating segment includes Physical therapy operations and Industrial injury prevention services. The company generates maximum revenue from the Physical therapy operations segment.
<h3>Unraveling the Financial Story of US Physical Therapy</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: US Physical Therapy's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 10.37%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: US Physical Therapy's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 4.21%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 1.46%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): US Physical Therapy's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 0.69%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.53.
<h2>The Significance of Analyst Ratings Explained</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Assessing US Physical Therapy: Insights From 5 Financial Analysts

WIIM

US Physical Therapy shares are trading higher after the company reported better-than-expected Q3 financial results.

US Physical Therapy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USPH#NYSE">USPH</a>) reported quarterly earnings of $0.69 per share which beat the analyst consensus estimate of $0.68 by 1.47 percent. This is a 11.29 percent increase over earnings of $0.62 per share from the same period last year. The company reported quarterly sales of $168.033 million which beat the analyst consensus estimate of $164.381 million by 2.22 percent. This is a 12.02 percent increase over sales of $150.007 million the same period last year.

Earnings

Earnings Beats

US Physical Therapy Q3 2024 Adj. EPS $0.69 Beats $0.68 Estimate, Sales $168.033M Beat $164.381M Estimate

US Physical Therapy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USPH#NYSE">USPH</a>) will release its quarterly earnings report on Tuesday, 2024-11-05. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate US Physical Therapy to report an earnings per share (EPS) of $0.68.
Anticipation surrounds US Physical Therapy's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Earnings Track Record</h3>
In the previous earnings release, the company missed EPS by $0.09, leading to a 9.29% drop in the share price the following trading session.
Here's a look at US Physical Therapy's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.82</td>
<td>0.55</td>
<td>0.57</td>
<td>0.61</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.73</td>
<td>0.51</td>
<td>0.59</td>
<td>0.62</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-9.0%</td>
<td>-2.0%</td>
<td>6.0%</td>
<td>-3.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1730746950_0.png" alt="eps graph" />
<h3>US Physical Therapy Share Price Analysis</h3>
Shares of US Physical Therapy were trading at $81.38 as of November 01. Over the last 52-week period, shares are down 1.81%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. 
<h3>Insights Shared by Analysts on US Physical Therapy</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on US Physical Therapy.
Analysts have provided US Physical Therapy with 4 ratings, resulting in a consensus rating of Outperform. The average one-year price target stands at $103.5, suggesting a potential 27.18% upside.
<h3>Peer Ratings Comparison</h3>
In this comparison, we explore the analyst ratings and average 1-year price targets of Brookdale Senior Living, Auna and Concentra Group Holdings, three prominent industry players, offering insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Outperform trajectory for Brookdale Senior Living, with an average 1-year price target of $8.0, suggesting a potential 90.17% downside.</li>
<li>As per analysts' assessments, Auna is favoring an Outperform trajectory, with an average 1-year price target of $13.5, suggesting a potential 83.41% downside.</li>
<li>The consensus among analysts is an Outperform trajectory for Concentra Group Holdings, with an average 1-year price target of $29.15, indicating a potential 64.18% downside.</li>
</ul>
<h3>Summary of Peers Analysis</h3>
Within the peer analysis summary, vital metrics for Brookdale Senior Living, Auna and Concentra Group Holdings are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>US Physical Therapy</td>
<td>Outperform</td>
<td>10.37%</td>
<td>$33.86M</td>
<td>1.46%</td>
</tr>
<tr>
<td>Brookdale Senior Living</td>
<td>Outperform</td>
<td>4.13%</td>
<td>$204.82M</td>
<td>-10.56%</td>
</tr>
<tr>
<td>Auna</td>
<td>Outperform</td>
<td>18.46%</td>
<td>$427.36M</td>
<td>0.24%</td>
</tr>
<tr>
<td>Concentra Group Holdings</td>
<td>Outperform</td>
<td>2.32%</td>
<td>$138.64M</td>
<td>6.97%</td>
</tr>
</tbody>
</table>

Key Takeaway:
US Physical Therapy ranks: 
- Top for Revenue Growth among peers. 
- Bottom for Gross Profit among peers. 
- Bottom for Return on Equity among peers.
<h3>Discovering US Physical Therapy: A Closer Look</h3>
US Physical Therapy Inc through its subsidiaries operates outpatient physical therapy clinics that provide pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers, and neurological-related injuries. The principal sources of payment for the clinics' services are managed care programs, commercial health insurance, Medicare/Medicaid, workers' compensation insurance, and proceeds from personal injury cases. Its operating segment includes Physical therapy operations and Industrial injury prevention services. The company generates maximum revenue from the Physical therapy operations segment.
<h3>Unraveling the Financial Story of US Physical Therapy</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Positive Revenue Trend: Examining US Physical Therapy's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 10.37% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: US Physical Therapy's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 4.21%, the company may face hurdles in effective cost management.
Return on Equity (ROE): US Physical Therapy's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 1.46%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.69%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: US Physical Therapy's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.53.
<a href="https://www.benzinga.com/quote/USPH/earnings">To track all earnings releases for US Physical Therapy visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Exploring US Physical Therapy's Earnings Expectations

U.S. Physical Therapy, Inc. (&quot;USPH&quot;) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USPH#NYSE">USPH</a>), a national operator of outpatient physical therapy clinics and provider of industrial injury prevention services, today announced that it has signed an agreement to purchase a 50% equity interest in a management services organization (the &quot;Company&quot;) that provides management and administrative services to 50 physical therapy clinics. The Company expects to close the transaction on October 31, 2024.
The Company manages 50 outpatient clinics, the majority of which are in New York, with plans to further expand in New York and adjacent states. The Company-managed clinics deliver physical, occupational and speech therapy and also provide physical therapy services to patients in their homes. Through its managed therapy providers, the Company currently generates approximately $64.0 million in annual revenue and approximately $12.0 million in annual EBITDA on a consolidated basis. The current owners of the Company will continue to have a 50% ownership interest. The Chief Executive Officer of the Company, who will remain with the Company as its executive leader, joined the Company in 2016 and has grown the group of managed clinics from five clinics to 50 clinics.

U.S. Physical Therapy Announces That It Has Signed An Agreement To Purchase A 50% Equity Interest In A Management Services Organization That Provides Management And Administrative Services To 50 Physical Therapy Clinics; No Financial Terms Disclosed

Wall Street started the week in the red, as traders weighed the economic and geopolitical fallout from escalating tensions in the Middle East. 
Monday marked the one-year anniversary of Hamas&#8217; October 7 attack, which triggered the <a href="https://www.benzinga.com/etfs/specialty-etfs/24/10/41210761/oil-surges-on-1-year-hamas-attack-anniversary-as-israel-mulls-iran-retaliation">ongoing war in Gaza</a>. The situation is now threatening to spread across the region, as Israel considers retaliating for last week&#8217;s missile attacks from Iran.
By 1 p.m. ET, the major indices were modestly lower, with the S&amp;P 500 down 0.5% and the Dow Jones off by 0.7%. The Nasdaq 100 also slid 0.5%. The energy sector was the only bright spot, buoyed by surging oil prices.
West Texas Intermediate (WTI) crude, as tracked by the United States Oil Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USO#NYSE">USO</a>), jumped over 3%, climbing to $77 per barrel. This rally marked its fifth consecutive session of gains, fueled by concerns that Israel may retaliate against Iran, a key oil producer, for its involvement in regional conflicts.
Last week&#8217;s blowout U.S. labor market data, coupled with rising oil prices and fresh stimulus measures out of China, pushed 10-year Treasury yields above 4%, setting the stage for the highest levels since late July. Investors appear increasingly wary of long-duration bonds, sending the iShares 20+ Year Treasury Bond ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLT#NASDAQ">TLT</a>) down 0.6%, extending its losing streak to four sessions.
Market sentiment around the Federal Reserve&#8217;s upcoming policy decisions has also shifted. The probability of the Fed refraining from cutting interest rates next month has dropped to just 17%, according to CME FedWatch Tool, 
Rising yields weighed heavily on metals, with gold down 0.4% to $2,645 per ounce and silver dropping 1.3%. Meanwhile, Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) gained 1.4%, trading at $63,682. 
<h1 class="wp-block-heading">Monday&#8217;s Performance In Major U.S. Indices, ETFs</h1>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>Chg %</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,724.31</td>
<td>-0.5%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>19,930.58</td>
<td>-0.5%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>42,059.07</td>
<td>-0.7%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,191.35</td>
<td>-0.8%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 1:30 p.m. ET</figcaption></figure>
According to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent100724&amp;t=be2bearmibe3na1">Benzinga Pro</a> data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)&nbsp;edged down 0.5% to $570.38.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>)&nbsp;fell 0.7% to $420.90.</li>
<li>The tech-heavy Invesco QQQ Trust Series (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) fell 0.5% to $485.21.</li>
<li>The iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) tumbled 0.8% to $218.77.</li>
<li>The Energy Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) outperformed, up 0.8%. The Utilities Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>) lagged, down 1.7%.</li>
</ul>
<h1 class="wp-block-heading">Monday&#8217;s Stock Movers</h1>
<ul>
<li>Super Micro Computer Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) rallied 14% after the company announced it is currently shipping more than 100,000 graphics processors per quarter and unveiled a new suite of liquid cooling products.</li>
<li>Everest Group Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EG#NYSE">EG</a>) plummeted over 8% after Morgan Stanley lowered its price target on the stock from $450 to $430.</li>
<li>Constellation Brands Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STZ#NYSE">STZ</a>) fell nearly 2% after Bank of America downgraded the stock from Outperform to Neutral and lowered the price target from $300 to $255. </li>
<li>Bank of America also downgraded several healthcare stocks including Concentra Group Holding Parent Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CON#NYSE">CON</a>), down 4.6%; AMN Healthcare Services Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMN#NYSE">AMN</a>), down 1.9%; Brookdale Senior Living (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKD#NYSE">BKD</a>), down 6% and U.S. Physical Therapy Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USPH#NYSE">USPH</a>), down 2.5%.</li>
</ul>
Read Now:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/10/41207490/s-p-500-could-reach-6-300-in-12-months-says-goldman-sachs-driven-by-strong-ai-demand-and-margin-">S&amp;P 500 Could Reach 6,300 In 12 Months, Says Goldman Sachs, Driven By &#8216;Strong AI Demand&#8217; And &#8216;Margin Expansion&#8217;</a></li>
</ul>
Image was created using artificial intelligence.

Equities

Broad U.S. Equity ETFs

Commodities

Global

Econ #s

Federal Reserve

Tech

ETFs

$BTC

SPDR Dow Jones Industrial Average ETF Trust

SMCI

iShares Trust Barclays 20+ Year Treasury Bond Fund

XLRE

Stocks Fall As Oil Prices Spike, 10-Year Yields Top 4%, Energy Sector Outperforms: What's Driving Markets Monday?

B of A Securities analyst Joanna Gajuk downgrades US Physical Therapy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USPH#NYSE">USPH</a>) from Buy to Neutral and lowers the price target from $114 to $90.

Downgrades

B of A Securities Downgrades US Physical Therapy to Neutral, Lowers Price Target to $90

Although U.S. stocks closed lower on Tuesday, there were a few notable insider trades.
When insiders purchase shares, it indicates their confidence in the company&#8217;s prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision.
Below is a look at a few recent notable insider purchases. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/">Benzinga&#8217;s insider transactions</a> platform.
<h3 class="wp-block-heading">Elastic</h3>
<ul>
<li>The Trade: Elastic N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESTC#NYSE">ESTC</a>) Director Paul R. Auvil III acquired a total of 20,000 shares at  an average price of $74.25. To acquire these shares, it cost around $1.48 million.</li>
<li>What's Happening: On Aug. 29, Elastic reported quarterly earnings of 35 cents per share, which beat the analyst consensus estimate of 25 cents per share.</li>
<li>What Elastic Does: Elastic is a software company based in Mountain View, California, focusing on search-adjacent products.</li>
</ul>
<h3 class="wp-block-heading">U.S. Physical Therapy</h3>
<ul>
<li>The Trade: U.S. Physical Therapy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USPH#NYSE">USPH</a>) Director Kathleen A Gilmartin acquired a total of 2,000 shares at an average price of $86.09. To acquire these shares, it cost around $172,180.</li>
<li>What's Happening: On Aug. 13, US Physical Therapy posted downbeat quarterly earnings.</li>
<li>What U.S. Physical Therapy Does: US Physical Therapy Inc through its subsidiaries operates outpatient physical therapy clinics that provide pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers, and neurological-related injuries.</li>
</ul>
<h3 class="wp-block-heading">CECO Environmental</h3>
<ul>
<li>The Trade: CECO Environmental Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CECO#NASDAQ">CECO</a>) Director Richard F Wallman <a href="https://www.benzinga.com/sec/insider-trades/">bought a total of 10,000 shares</a> at an average price of $28.77. To acquire these shares, it cost around $1.98 million. The company's President and CEO also bought $287,722 shares.</li>
<li>What's Happening: On July 30, CECO Environmental reported worse-than-expected second-quarter revenue results and raised its FY24 revenue guidance above estimates.</li>
<li>What CECO Environmental Does: CECO Environmental Corp serves the energy, industrial, and other niche markets.</li>
</ul>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/24/09/40700380/dollar-tree-dicks-sporting-goods-and-3-stocks-to-watch-heading-into-wednesday">Dollar Tree, Dick&#8217;s Sporting Goods And 3 Stocks To Watch He</a><a href="https://www.benzinga.com/24/09/40700380/dollar-tree-dicks-sporting-goods-and-3-stocks-to-watch-heading-into-wednesday">ading Into Wednesday</a></li>
</ul>

$1.5M Bet On Elastic? Check Out These 4 Stocks Executives Are Buying

The Company acquired a&nbsp;70%&nbsp;interest in the Company with the current owners retaining a&nbsp;30%&nbsp;ownership interest.

U.S. Physical Therapy Acquires A Physical Therapy And Hand Therapy Practice With Eight Clinic Locations In Pennsylvania Which Currently Generates ~$5.5M In Annual Revenues

Graham Reeve, COO at US Physical Therapy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USPH#NYSE">USPH</a>), reported an insider sell on August 21, according to a new SEC filing. 
What Happened: According to a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000885978/000095017024099579//Archives/edgar/data/885978/000095017024099579/0000950170-24-099579-index.htm">U.S. Securities and Exchange Commission</a> on Wednesday, Reeve sold 1,724 shares of US Physical Therapy. The total transaction value is $142,230.
At Thursday morning, US Physical Therapy shares are down by 0.0%, trading at $83.11.
<h3>Delving into US Physical Therapy's Background</h3>
US Physical Therapy Inc through its subsidiaries operates outpatient physical therapy clinics that provide pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers, and neurological-related injuries. The principal sources of payment for the clinics' services are managed care programs, commercial health insurance, Medicare/Medicaid, workers' compensation insurance, and proceeds from personal injury cases. Its operating segment includes Physical therapy operations and Industrial injury prevention services. The company generates maximum revenue from the Physical therapy operations segment.
<h3>A Deep Dive into US Physical Therapy's Financials</h3>
Revenue Growth: US Physical Therapy's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 10.37%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Profitability Metrics:
<ul>
<li>
Gross Margin: The company faces challenges with a low gross margin of 20.25%, suggesting potential difficulties in cost control and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): US Physical Therapy's EPS is below the industry average. The company faced challenges with a current EPS of 0.47. This suggests a potential decline in earnings.
</li>
</ul>
Debt Management: US Physical Therapy's debt-to-equity ratio is below the industry average. With a ratio of 0.53, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
Financial Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: With a higher-than-average P/E ratio of 83.95, US Physical Therapy's stock is perceived as being overvalued in the market.
</li>
<li>
Price to Sales (P/S) Ratio: With a higher-than-average P/S ratio of 1.99, US Physical Therapy's stock is perceived as being overvalued in the market, particularly in relation to sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): With an EV/EBITDA ratio of 19.93, the company's market valuation exceeds industry averages.
</li>
</ul>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Uncovering the Importance of Insider Activity</h3>
Investors should view insider transactions as part of a multifaceted analysis and not rely solely on them for decision-making.
Exploring the legal landscape, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated by Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and major hedge funds. These insiders are required to report their transactions through a Form 4 filing, which must be submitted within two business days of the transaction.
Highlighted by a company insider's new purchase, there's a positive anticipation for the stock to rise.
But, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>The Insider's Guide to Important Transaction Codes</h3>
In the domain of transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> frequently turn their focus to those taking place in the open market, as meticulously outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000885978">Check Out The Full List Of US Physical Therapy's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

COO Of US Physical Therapy Makes $142K Sale

Concentra Group Holdings Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CON#NYSE">CON</a>) priced in July its initial public offering of 22.5 million shares <a href="https://www.benzinga.com/pressreleases/24/07/n39947510/select-medical-holdings-corporation-announces-pricing-of-concentra-group-holdings-parent-inc-initi" target="_blank" rel="noreferrer noopener">at $23.50 per share</a>.
RBC Capital Markets initiated coverage of Concentra, citing a &#8220;differentiated operating and reimbursement model with strong growth.&#8221;
RBC Capital analyst Ben Hendrix wrote Concentra offers a unique investment strategy with minimal exposure to regulatory and payor negotiation challenges faced by other providers, as its revenue mainly comes from employers and workers compensation rather than government or managed care reimbursements.
&#8220;We see upside to Concentra&#8217;s post-IPO trading levels based on the company&#8217;s dominant market position as the country&#8217;s leading occupational healthcare provider,&#8221; RBC Capital noted.
The analyst initiated with an Outperform rating and a price target of $33.
Also Read: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40446983/concentras-high-quality-business-model-attracts-analyst-attention-initiates-with-bu" target="_blank" rel="noreferrer noopener">Concentra&#8217;s High-Quality Business Model Attracts Analyst Attention, Initiates With Buy Rating</a>.
Since the IPO, Concentra&#8217;s trading performance has closely mirrored that of its parent company, Select Medical Holdings Corp.&#8217;s subsidiary (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SEM#NYSE">SEM</a>).
RBC Capital wrote that this valuation is too low for an independent entity with stronger profit margins and a more favorable reimbursement profile than Medicare-reimbursed post-acute care providers.
Although Concentra lacks direct public peers, RBC Capital analyst sees high-margin outpatient operators focused on musculoskeletal cases, such as Surgery Partners Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGRY#NASDAQ">SGRY</a>) and U.S. Physical Therapy Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USPH#NYSE">USPH</a>), as suitable comparisons.
Given Concentra&#8217;s more favorable reimbursement structure, the analyst expects its valuation to approach the 14.0x target as management executes its expansion plans and taps into a robust pipeline of growth opportunities.
Concentra provides occupational and consumer health services and other direct-to-employer care to more than 50,000 patients each day on average from 547 occupational health centers in 41 states and 154 onsite health clinics.
The company has 11,000 employees.
CON Price Action: Concentra Group Holdings stock is down 0.73% at $23.18 at publication Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/08/40467815/arbitration-to-uncover-hidden-value-of-hess-guyana-oil-assets-in-exxon-mobil-vs-chevron-dispute-" target="_blank" rel="noreferrer noopener">Arbitration To Uncover Hidden Value Of Hess&#8217; Guyana Oil Assets In Exxon Mobil vs. Chevron Dispute: Report</a>.</li>
</ul>
Photo: This Is Engineering via Upsplash

Analyst Color

Health Care

Initiation

Movers

General

SGRY

Concentra's Post-IPO Trading Levels Based On 'Its Dominant Market Position,' Says Analyst

Barrington Research analyst Michael Petusky maintains US Physical Therapy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USPH#NYSE">USPH</a>) with a Outperform and lowers the price target from $122 to $108.

Barrington Research Maintains Outperform on US Physical Therapy, Lowers Price Target to $108

Guidance

U.S. Physical Therapy Returned Its Guidance For Adjusted EBITDA For 2024 To Its Original Range Of $80M-$85M

US Physical Therapy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USPH#NYSE">USPH</a>) reported quarterly earnings of $0.73 per share which missed the analyst consensus estimate of $0.82 by 10.98 percent. This is a 3.95 percent decrease over earnings of $0.76 per share from the same period last year. The company reported quarterly sales of $167.19 million which beat the analyst consensus estimate of $162.35 million by 2.98 percent. This is a 10.37 percent increase over sales of $151.49 million the same period last year.

Earnings Misses

US Physical Therapy Q2 Adj $0.73 Misses $0.82 Estimate, Sales $167.19M Beat $162.35M Estimate

Investors looking for stocks in the Medical - Outpatient and Home Healthcare sector might want to consider either Amedisys (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/amed#NASDAQ">AMED</a>) or U.S. Physical Therapy (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/usph#NYSE">USPH</a>). But which of these two stocks is more attractive to value investors? We&#39;ll need to take a closer look to find out.
There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The proven Zacks Rank emphasizes companies with positive estimate revision trends, and our Style Scores highlight stocks with specific traits.
Amedisys has a Zacks Rank of #2 (Buy), while U.S. Physical Therapy has a Zacks Rank of #3 (Hold) right now. Investors should feel comfortable knowing that AMED likely has seen a stronger improvement to its earnings outlook than USPH has recently. But this is just one factor that value investors are interested in.
Value investors are also interested in a number of tried-and-true valuation metrics that help show when a company is undervalued at its current share price levels.
Our Value category highlights undervalued companies by looking at a variety of key metrics, including the popular P/E ratio, as well as the P/S ratio, earnings yield, cash flow per share, and a variety of other fundamentals that have been used by value investors for years.
AMED currently has a forward P/E ratio of 21.14, while USPH has a forward P/E of 34.11. We also note that AMED has a PEG ratio of 2.37. This figure is similar to the commonly-used P/E ratio, with the PEG ratio also factoring in a company&#39;s expected earnings growth rate. USPH currently has a PEG ratio of 3.77.
Another notable valuation metric for AMED is its P/B ratio of 2.80. The P/B ratio is used to compare a stock&#39;s market value with its book value, which is defined as total assets minus total liabilities. For comparison, USPH has a P/B of 3.04.
These are just a few of the metrics contributing to AMED&#39;s Value grade of B and USPH&#39;s Value grade of C.
AMED is currently sporting an improving earnings outlook, which makes it stick out in our Zacks Rank model. And, based on the above valuation metrics, we feel that AMED is likely the superior value option right now.
<a href="https://www.zacks.com/stock/news/2310183/amed-vs-usph-which-stock-is-the-better-value-option?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_3-2310183">To read this article on Zacks.com click here.</a>

Small Cap

AMED

AMED vs. USPH: Which Stock Is the Better Value Option?

U.S. Physical Therapy Non-GAAP EPS of $0.55 misses by $0.13, revenue of $168.03M beats by $3.65M

Reports Q3 revenue $168.033M, consensus $164.38M. Chris Reading, Chief Executive Officer, said, "In any challenging environment, action is necessar...

U.S. Physical Therapy reports Q3 adjusted EPS 55c, consensus 68c

U.S. Physical Therapy declares $0.44 dividend

Bank of America Securities analyst Joanna Gajuk maintained a Hold rating on US Physical Therapy (USPH – Research Report) today. The company's share...

US Physical Therapy (USPH) Receives a Hold from Bank of America Securities

U.S. Physical Therapy, Inc. (USPH) Q3 2024 Earnings Call Transcript

U.s. Physical Therapy ( ($USPH) ) has released its Q3 earnings. Here is a breakdown of the information U.s. Physical Therapy presented to its inves...

U.S. Physical Therapy Reports Strong Q3 2024 Growth

An update from US Physical Therapy ( ($USPH) ) is now available. U.S. Physical Therapy, Inc., a leading provider of outpatient physical therapy and...

US Physical Therapy Executives to Present at Conferences

Meeting to be held in Denver on November 18-19 hosted by Barrington. Published first on TheFly – the ultimate source for real-time, market-moving b...

U.S. Physical Therapy management to meet with Barrington

Catalyst Watch: Nvidia earnings, Microsoft Ignite, crypto confidence, and P&G event

Analyst Michael Petusky from Barrington maintained a Buy rating on US Physical Therapy (USPH – Research Report) and keeping the price target at $10...

US Physical Therapy's Strong Performance and Strategic Initiatives Drive Buy Rating with $108 Price Target

ABIT

ASAN

BIDU

BILL

BKKT

BRBR

BRPHF

BTBT

CRNC

CRWS

EDIT

FCEL

FTNT

FWONA

GEHC

HNST

HYMTF

INOD

INTU

IONS

JACK

JAKK

MARA

MNDY

MRUS

MSTR

MVIS

NAPA

NVDA

ORCL

PANW

PCOR

PYCR

QGEN

QUAD

RIOT

ROST

RVTY

SAVE

SNOW

STLA

STNG

TCOM

TRMD

VLKAF

XPEV

Press Releases

U.S. Physical Therapy to Present at the CJS Securities 24th Annual New Ideas Summer Conference

U.S. Physical Therapy, Inc. Schedules Second Quarter 2024 Earnings Release and Conference Call

U.S. Physical Therapy Reports Second Quarter 2024 Results

U.S. Physical Therapy to Present at the 15th Annual Midwest IDEAS Investor Conference

U.S. Physical Therapy Announces the Acquisition of an Eight-Clinic Physical Therapy Practice

U.S. Physical Therapy Announces Acquisition of 50-Clinic Physical Therapy Management Services Organization

U.S. Physical Therapy, Inc. Schedules Third Quarter 2024 Earnings Release and Conference Call

U.S. Physical Therapy Completes Acquisition of 50-Clinic Physical Therapy Practice

U.S. Physical Therapy Reports Third Quarter 2024 Results

U.S. Physical Therapy to Present at the Stephens Annual Investment Conference and 16th Annual Southwest IDEAS Conference

Comments

US Physical Therapy

Notizie

Ultime notizie per US Physical Therapy (NYSE:USPH) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO